Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer
April 27 2020 - 8:30AM
Business Wire
Seasoned industry executive with experience
leading global joint preservation and restoration businesses
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
joint preservation and regenerative therapies company with products
leveraging its proprietary hyaluronic acid (HA) technology
platform, today announced that Cheryl R. Blanchard, Ph.D., has been
named President and Chief Executive Officer, effective April
26,2020. Dr. Blanchard has served as interim Chief Executive
Officer of Anika since February 2020 and as a member of the
Company’s Board of Directors since August 2018. Dr. Blanchard has
more than 25 years of executive management experience with deep
expertise in orthopedic medical devices, regenerative medicine and
drug delivery.
“After a thorough and thoughtful search process, we are thrilled
to appoint Dr. Blanchard as President and CEO of Anika,” said Dr.
Joseph Bower, Chairman of Anika's Board of Directors. “Cheryl has
successfully developed and led orthopedic, regenerative medicine
and drug delivery companies through periods of substantial growth.
Since joining Anika’s Board in 2018, we have benefitted from
Cheryl’s global commercial expertise and significant operational,
strategic, and M&A experience. Most recently, as interim CEO,
Cheryl has been integral in implementing the Company’s strategic
plan and navigating a challenging economic environment. These
skills and experiences position her as the ideal person to lead
Anika through its next phase of growth.”
“I am honored to lead Anika during this transformative time in
its evolution and growth,” said Dr. Blanchard. “During my time on
Anika’s Board, I gained unique insight into the Company’s business,
strategy and operations, and I am confident in the strength of its
market position and growth prospects. I am excited to continue
working closely with the Anika leadership team and Board as well as
the company’s talented employees who, particularly as we navigate
the COVID-19 pandemic, have demonstrated incredible resolve and
commitment to serving patients and advancing our objectives.
Through the continued execution of our strategic plan, we expect to
build on our leadership position in the joint preservation and
restoration market.”
Prior to joining Anika, Dr. Blanchard served as President and
Chief Executive Officer of Microchips Biotech, Inc., a
biotechnology company developing regenerative medicine and drug
delivery products, from 2014 until its sale to Daré Bioscience,
Inc. in November 2019. From 2000 to 2012, she served in various
officer positions of Zimmer, Inc. (now Zimmer Biomet), a medical
device company focused on musculoskeletal products, including as
the Senior Vice President, Corporate Chief Scientific Officer and
General Manager of its Biologics Business. She was also a member of
Zimmer’s executive committee and founded, built and led Zimmer’s
Joint Preservation/Regenerative Medicine business. Before joining
Zimmer, Dr. Blanchard built and led the medical device and
regenerative medicine practice at Southwest Research Institute. Dr.
Blanchard received her M.S. and Ph.D. in Materials Science and
Engineering at the University of Texas at Austin and received her
B.S. in Ceramic Engineering at Alfred University. Dr. Blanchard is
a member of the National Academy of Engineering.
Until her appointment as interim Chief Executive Officer of
Anika in February 2020, Dr. Blanchard served as a member of Anika’s
Compensation Committee and Governance and Nominating Committee. She
has served as a director of Neuronetics (NASDAQ: STIM) since
February 2019 and a director of Daré Bioscience, Inc. (NASDAQ:
DARE) since November 2019. Dr. Blanchard also serves on the Board
of a privately held company in the life sciences industry. Click
here to view her full bio.
About Anika Therapeutics
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
joint preservation and regenerative therapies company based in
Bedford, Massachusetts. Anika is committed to delivering therapies
to improve the lives of patients across a continuum of care from
osteoarthritis pain management to joint preservation and
restoration. The Company has over two decades of global expertise
commercializing more than 20 products based on its proprietary
hyaluronic acid (HA) technology platform. For more information
about Anika, please visit www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200427005206/en/
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung,
781-457-9000 Chief Financial Officer
investorrelations@anikatherapeutics.com
For Media Inquiries: W2O Group Jeremy Berrington, 312-241-1995
jberrington@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Sep 2023 to Sep 2024